|
18.02.2016 23:30:00
|
Moody's: Growing biosimilar pipelines pose long-term threat to branded pharma companies
New York, February 18, 2016 -- The growing multitude of biosimilar products in clinical development presents challenges for branded biotech companies in the long term, including Amgen Inc. (Baa1 stable), AbbVie Inc. (Baa1 negative), Johnson & Johnson (Aaa stable) and Roche Holding AG (A1 stable), says Moody's Investors Service. Biosimilar products are follow-on versions of complex biotech drugs.
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.